Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to the market innovative stem cell-based therapies for regenerative medicine. The first proprietary cellular therapy of Novadip Biosciences is a totally differentiated and 3D osteogenic scaffold-free structure which provide innovative treatments for severe bone healing disorders. Their lead product NVD-001 introduces new principles of guided tissue regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture 3D natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects. In September 2015, NOVADIP has closed EUR 28 million Series A Round with US and Belgian investors to advance his breakthrough cell therapy pipeline. Phone number : +32/10 77 92 20 E-mail : info@novadip.com VAT : BE0535.575.602 Privacy policy : https://www.novadip.com/privacy-policy-2/